| T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia A Mardiros, C Dos Santos, T McDonald, CE Brown, X Wang, LE Budde, ... Blood, The Journal of the American Society of Hematology 122 (18), 3138-3148, 2013 | 443 | 2013 |
| Antileukemic activity of rapamycin in acute myeloid leukemia C Récher, O Beyne-Rauzy, C Demur, G Chicanne, C Dos Santos, ... Blood 105 (6), 2527-2534, 2005 | 406 | 2005 |
| SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells L Li, T Osdal, Y Ho, S Chun, T McDonald, P Agarwal, A Lin, S Chu, J Qi, ... Cell stem cell 15 (4), 431-446, 2014 | 246 | 2014 |
| A critical role for Lyn in acute myeloid leukemia C Dos Santos, C Demur, V Bardet, N Prade-Houdellier, B Payrastre, ... Blood, The Journal of the American Society of Hematology 111 (4), 2269-2279, 2008 | 189 | 2008 |
| Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells AG Renner, C Dos Santos, C Recher, C Bailly, L Créancier, A Kruczynski, ... Blood, The Journal of the American Society of Hematology 114 (3), 659-662, 2009 | 173 | 2009 |
| The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia N Gallay, C Dos Santos, L Cuzin, M Bousquet, V Simmonet Gouy, ... Leukemia 23 (6), 1029-1038, 2009 | 156 | 2009 |
| The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents C Dos Santos, T McDonald, YW Ho, H Liu, A Lin, SJ Forman, YH Kuo, ... Blood, The Journal of the American Society of Hematology 122 (11), 1900-1913, 2013 | 120 | 2013 |
| Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies EC Pietsch, J Dong, R Cardoso, X Zhang, D Chin, R Hawkins, T Dinh, ... Blood cancer journal 7 (2), e536-e536, 2017 | 119 | 2017 |
| mTOR, a new therapeutic target in acute myeloid leukemia Rà Christian, DS Cé dric, D Cé cile, P Bernard Cell Cycle 4 (11), 1540-1549, 2005 | 116 | 2005 |
| Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity DMS Hossain, C Dos Santos, Q Zhang, A Kozlowska, H Liu, C Gao, ... Blood, The Journal of the American Society of Hematology 123 (1), 15-25, 2014 | 114 | 2014 |
| A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220 P Hou, C Wu, Y Wang, R Qi, D Bhavanasi, Z Zuo, C Dos Santos, S Chen, ... Cancer research 77 (16), 4402-4413, 2017 | 105 | 2017 |
| Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option H Stamm, F Klingler, EM Grossjohann, J Muschhammer, E Vettorazzi, ... Oncogene 37 (39), 5269-5280, 2018 | 103 | 2018 |
| CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells R Jitschin, D Saul, M Braun, S Tohumeken, S Völkl, R Kischel, ... Journal for immunotherapy of cancer 6, 1-6, 2018 | 89 | 2018 |
| Uncoupling between immunological synapse formation and functional outcome in human γδ T lymphocytes B Favier, E Espinosa, J Tabiasco, C Dos Santos, M Bonneville, S Valitutti, ... The Journal of Immunology 171 (10), 5027-5033, 2003 | 54 | 2003 |
| Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells M Krevvata, X Shan, C Zhou, C Dos Santos, GH Ndikuyeze, A Secreto, ... Haematologica 103 (6), 959, 2018 | 52 | 2018 |
| A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway? AG Renner, L Créancier, C Dos Santos, C Fialin, C Recher, C Bailly, ... Cell cycle 9 (9), 1690-1696, 2010 | 34 | 2010 |
| Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or … S Ganguly, JE Cortes, A Krämer, MJ Levis, G Martinelli, AE Perl, ... Transplantation and Cellular Therapy 27 (2), 153-162, 2021 | 33 | 2021 |
| Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia AH Wei, JM Ribera, RA Larson, D Ritchie, A Ghobadi, Y Chen, ... Leukemia 35 (8), 2220-2231, 2021 | 32 | 2021 |
| The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia C Dos Santos, C Récher, C Demur, B Payrastre Bulletin du cancer 93 (5), 445-447, 2006 | 25 | 2006 |
| Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia H Kiyoi, JD Morris, I Oh, Y Maeda, H Minami, T Miyamoto, T Sakura, H Iida, ... Cancer science 111 (4), 1314-1323, 2020 | 24 | 2020 |
